Repligen Completes Acquisition of BioLife Solutions
July 23, 2026
Repligen agreed to acquire BioLife Solutions in a cash-and-stock transaction valued at approximately $1.5 billion, and later announced that the acquisition was completed. The deal expands Repligen’s cell and gene therapy offering with BioLife’s biopreservation media and cell-processing products, while broadening BioLife’s access to Repligen’s global commercial reach.
- Buyers
- Repligen
- Targets
- BioLife Solutions
- Industry
- Medical Devices
- Location
- Washington, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
BioLife Solutions Acquires PanTHERA CryoSolutions
April 10, 2025
Biotechnology
BioLife Solutions acquired the remaining 90% of PanTHERA CryoSolutions for $9.3 million in cash plus 241,355 shares of BioLife common stock, with up to an additional $7.2 million of stock payable upon achievement of milestones. The acquisition adds PanTHERA's proprietary Ice Recrystallization Inhibitor (IRI) technology and scientific talent to BioLife's biopreservation consumables portfolio, accelerating product capability development for the cell and gene therapy market.
-
1315 Capital Acquires SciSafe from BioLife Solutions
November 14, 2024
Healthcare Services
1315 Capital, a Philadelphia-based growth equity firm, has acquired SciSafe from BioLife Solutions in an all-cash transaction that establishes SciSafe as an independent, standalone biostorage company. The deal accompanies a growth capital investment to fund expansion of SciSafe's biostorage, cold-chain and compliance capabilities and to support global footprint growth.
-
Discovery Life Sciences Acquires ReachBio Research Labs
April 11, 2023
Biotechnology
Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.
-
PerkinElmer Acquires BioLegend for Approximately $5.25 Billion
July 26, 2021
Biotechnology
PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.
-
Repligen Corporation Acquires ARTeSYN Biosolutions for $200M
October 28, 2020
Medical Devices
Repligen Corporation has agreed to acquire privately-held ARTeSYN Biosolutions for approximately $200 million (about $130 million cash and $70 million in Repligen stock). The purchase expands Repligen's single-use downstream bioprocessing systems portfolio — ARTeSYN was projected to generate roughly $30 million in pro forma 2020 revenue and the deal complements Repligen's recent EMT and NMS acquisitions.
-
BioLife Solutions Acquires SciSafe
September 21, 2020
Healthcare Services
BioLife Solutions, Inc. (NASDAQ: BLFS) has entered into a definitive agreement to acquire SciSafe, a privately held multi-facility biostorage provider serving the cell and gene therapy and pharmaceutical industries. BioLife will pay $15 million cash and $15 million in newly issued BioLife common shares for 100% of SciSafe, with up to 626,000 additional shares earnable based on revenue milestones; the deal is expected to close on September 30.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.